Bicara Therapeutics (BCAX) Cash from Operations (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Cash from Operations of 37508000.0 for Q1 2026, down 33.45% year-over-year from 56362267.32 in Q1 2025, and down 57.03% quarter-over-quarter from 23886000.0 in Q4 2025.
Bicara Therapeutics (BCAX) Cash from Operations (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Cash from Operations history runs 4 years deep, the most recent figure standing at 37508000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 33.45% year-over-year to 37508000.0; the TTM figure through Mar 2026 stood at 116236000.0 (down 31.68% YoY), while the FY2025 annual figure was 106834000.0, down 42.92% from the prior year.
- Cash from Operations for Q1 2026 stood at 37508000.0, down from 23886000.0 in the prior quarter.
- The five-year high for Cash from Operations was 8036000.0 in Q4 2023, with the low at 37508000.0 in Q1 2026.
- The 4-year median for Cash from Operations is 24740000.0 (2025), against an average of 22712900.0.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations plunged 273.72% in 2024, then climbed 20.46% in 2025.
- Bicara Therapeutics' Cash from Operations stood at 8036000.0 in 2023, then slumped by 273.72% to 30032000.0 in 2024, then advanced by 20.46% to 23886000.0 in 2025, then sank by 57.03% to 37508000.0 in 2026.
- Business Quant data shows BCAX's Cash from Operations at 37508000.0 in Q1 2026, 23886000.0 in Q4 2025, and 29248000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | -44.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44.21 Mn |
| Jun 30, 2026 | -44.21 Mn |
| Mar 31, 2026 | -37.51 Mn |
| Mar 31, 2026 | -37.51 Mn |
| Dec 31, 2025 | -23.89 Mn |
| Dec 31, 2025 | -23.89 Mn |
| Sep 30, 2025 | -29.25 Mn |
| Sep 30, 2025 | -29.25 Mn |
| Jun 30, 2025 | -25.59 Mn |
| Jun 30, 2025 | -25.59 Mn |
| Mar 31, 2025 | -28.11 Mn |
| Mar 31, 2025 | -28.11 Mn |
| Dec 31, 2024 | -30.03 Mn |
| Dec 31, 2024 | -30.03 Mn |
| Sep 30, 2024 | -17.22 Mn |
| Sep 30, 2024 | -17.22 Mn |
| Jun 30, 2024 | -12.91 Mn |
| Jun 30, 2024 | -12.91 Mn |
| Mar 31, 2024 | -14.59 Mn |
| Mar 31, 2024 | -14.59 Mn |